Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-54452840 · 1 trial · 1 indication
Serum concentrations of JNJ-54452840 will be used to determine pharmacokinetic parameters for JNJ-54452840
| Arm | Type | Description |
|---|---|---|
| Group A: JNJ-54452840 20 mg | EXPERIMENTAL | Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: JNJ-54452840 80 mg | EXPERIMENTAL | Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: JNJ-54452840 240 mg | EXPERIMENTAL | Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: Placebo | PLACEBO_COMPARATOR | Each participant will receive matching placebo as a single intravenous dose. |
| Group B: JNJ-54452840 20 mg | EXPERIMENTAL | Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: JNJ-54452840 80 mg | EXPERIMENTAL | Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: JNJ-54452840 240 mg | EXPERIMENTAL | Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: Placebo | PLACEBO_COMPARATOR | Each participant will receive matching placebo as a single intravenous dose. |
| Name | Type | Description |
|---|---|---|
| JNJ-54452840 | DRUG | Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg |
| Placebo | OTHER | Single matching intravenous dose |
Inclusion Criteria: * Must be a healthy male with no clinically relevant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments - Must be Japanese or Caucasian * Japanese participants must have been born in Japan, have resided outs...
JNJ-54452840 is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other. It is not approved by the FDA and remains in clinical testing.
JNJ-54452840 is being studied for use in healthy participants. The completed Phase 1 trial assessed the pharmacokinetics and safety of single doses of the drug in healthy Japanese and Caucasian participants. It is not intended for a specific disease indication at this stage of development.
JNJ-54452840 is developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 clinical trial of this investigational small molecule.
JNJ-54452840 is in Phase 1 clinical development. The drug is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
JNJ-54452840 has one completed Phase 1 trial, NCT01809353, titled 'To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants.' The trial enrolled 32 male participants in the United States and was placebo-controlled and double-blinded.